RESERVED CONTENT
Access to this content is free for full ISTH members, and Academy members and others can purchase access for $25 USD.
About this activity
Discussion Forum (0)
Rate & Comment (0)
This live session was hosted on:
May 27, 2022 14:30-15:30 UTC
Session Description:
This webinar will feature talks by Prof. Mettine Bos and Dr. Laurent Mosnier on their exciting research on mutants of hemostatic proteins as potential therapeutics.
Event Outline:
- Introduction by Dr. Colin Kretz
- Engineering of Activated Factor V as Therapy for Severe Bleeding - Super Factor Va- Laurent Mosnier, Ph.D. (~20 minutes)
- Recombinant Factor X Variants as DOAC Antidotes - from Snake Venom to Therapeutic Protein- Mettine Bos, Ph.D. (~20 minutes)
- Q&A with audience (15 minutes)
Learning Objectives:
Engineering of Activated Factor V as Therapy for Severe Bleeding - Super Factor Va
- Understanding different mechanisms that can contribute to bleeding in settings of Hemophilia, DOACs, and Acute Traumatic Coagulopathy (ATC)
- Learn how engineering of activated Factor V can target the different mechanisms that contribute to bleeding
- Understand the biochemistry and mechanism of action of modifications in factor X(a) to overcome inhibition by factor Xa-inhibiting direct oral anticoagulants
- Learn how a snake venom toxin can form the basis for a factor X-based bypassing agent with therapeutic potential
This webinar is free for full ISTH members and $25 USD for Academy members. Academy membership and student membership is free, and other membership rates are as low as $35 USD. Learn more about membership and join today here.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}